Japan health ministry panel approves Novavax's COVID-19 vaccine

1 minute read

A vial and sryinge are seen in front of a displayed Novavax logo in this illustration taken January 11, 2021. REUTERS/Dado Ruvic/Illustration

Register now for FREE unlimited access to Reuters.com

TOKYO, April 18 (Reuters) - A Japanese Health Ministry committee said on Monday it has approved Novavax Inc's (NVAX.O) COVID-19 vaccine, setting the stage for full approval of the country's fourth shot for the coronavirus.

The Japanese government has agreed to purchase 150 million doses of Novavax's recombinant protein type vaccine, which is to be manufactured domestically by Takeda Pharmaceutical Co. .

Most of Japan's COVID vaccinations have been carried out with the mRNA types made by Pfizer Inc (PFE.N) and Moderna Inc (MRNA.O). Astrazeneca Plc's (AZN.L) shot has also been approved, but most domestically produced supplies have not been used in Japan and instead donated overseas.

Register now for FREE unlimited access to Reuters.com
Reporting by Daniel Leussink; Editing by Toby Chopra and Hugh Lawson

Our Standards: The Thomson Reuters Trust Principles.